11 completed, 9 terminated, 4 recruiting, 2 withdrawn. 28 Phase 2, 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 28 | Completed 11, Terminated 9, Recruiting 4, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 11 | Completed 5, Recruiting 3, Terminated 2, Active not recruiting 1 |
Follow Arrowhead Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis ARO-INHBE, Placebo - Metabolic Dysfunction-Associated Steatohepatitis | Phase 2 | Not yet recruiting | Arrowhead Pharmaceuticals | 252 | 2026-09-01 | 2026-10-06 |
| Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma ARO-RAGE, Placebo - Asthma | Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 36 | 2026-03-30 | 2026-10-01 |
| Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia ARO-DIMERPA, Placebo - Hyperlipidemia; Mixed | Phase 1 / Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 78 | 2025-12-22 | 2026-10-13 |
| Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease ARO-MAPT-SC, Placebo - Alzheimer Disease, Alzheimer Disease, Early Onset | Phase 1 / Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 112 | 2025-11-18 | 2026-09-18 |
| A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus ARO-ALK7, Placebo - Obesity, Diabetes Mellitus, Type 2 | Phase 1 / Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 150 | 2025-05-09 | 2026-07-08 |
| A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus ARO-INHBE, Placebo, Tirzepatide - Obesity | Phase 1 / Phase 2 | Active not recruiting | Arrowhead Pharmaceuticals | 190 | 2024-12-04 | 2026-10-30 |
| Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis ARO-MMP7 Inhalation Solution, Placebo - Idiopathic Pulmonary Fibrosis | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 105 | 2023-01-30 | 2026-08-05 |
| Study of ARO-APOC3 in Adults With Dyslipidemia ARO-APOC3 - Dyslipidemias | Phase 2 | Completed | Arrowhead Pharmaceuticals | 418 | 2022-07-07 | 2026-05-12 |
| Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease ARO-RAGE, Placebo - Asthma | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 127 | 2022-06-29 | 2026-04-09 |
| Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease ARO-MUC5AC, Placebo - Asthma, Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Terminated | Arrowhead Pharmaceuticals | 78 | 2022-06-27 | 2026-09-14 |
| Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) ARO-ANG 3 Injection - Homozygous Familial Hypercholesterolemia | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 18 | 2022-04-22 | 2026-06-12 |
| Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease ARO-C3, Placebo - C3 Glomerulopathy, IgA Nephropathy | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 62 | 2022-02-01 | 2026-05-22 |
| Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia ARO-APOC3, Placebo - Mixed Dyslipidemia | Phase 2 | Completed | Arrowhead Pharmaceuticals | 353 | 2021-09-28 | 2026-04-14 |
| Study of ARO-ANG3 in Adults With Mixed Dyslipidemia ARO-ANG3, Placebo - Mixed Dyslipidemia | Phase 2 | Completed | Arrowhead Pharmaceuticals | 204 | 2021-06-28 | 2025-12-03 |
| Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia ARO-APOC3, Placebo - Severe Hypertriglyceridemia | Phase 2 | Completed | Arrowhead Pharmaceuticals | 229 | 2021-05-31 | 2026-03-24 |
| Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis ARO-ENaC, Placebo - Cystic Fibrosis, Pulmonary | Phase 1 / Phase 2 | Terminated | Arrowhead Pharmaceuticals | 43 | 2020-07-30 | 2025-12-17 |
| Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH ARO-HSD Injection, sterile normal saline (0.9% NaCl) - Non-alcoholic Steatohepatitis | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 50 | 2020-03-03 | 2025-10-03 |
| Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD) ARO-AAT - Alpha 1-Antitrypsin Deficiency | Phase 2 | Completed | Arrowhead Pharmaceuticals | 16 | 2019-10-31 | 2025-10-15 |
| Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) Fazisiran Injection, Placebo - Alpha 1-Antitrypsin Deficiency | Phase 2 | Completed | Arrowhead Pharmaceuticals | 40 | 2019-08-07 | 2025-11-04 |
| Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV) ARO-HBV, Sterile Normal Saline (0.9% NaCl), JNJ-56136379 - Hepatitis B | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 114 | 2018-03-27 | 2025-10-22 |
Showing 20 of 28. Sign in to see all of them.
Hepatitis B (7) · Asthma (3) · Hepatitis B, Chronic (3) · alpha 1-Antitrypsin Deficiency (3) · Obesity (2) · Alzheimer Disease (1) · Cystic Fibrosis (1) · Diabetes Mellitus, Type 2 (1) · Dyslipidemias (1) · Glomerulonephritis, IGA (1) · Hepatitis (1) · Hepatitis D (1) · Homozygous Familial Hypercholesterolemia (1) · Hyperlipoproteinemia Type II (1) · Hypertriglyceridemia (1)
ARC-520 (7) · entecavir (6) · Tenofovir (5) · Histamine Antagonists (4) · Chlorpheniramine (1) · Diphenhydramine (1) · JNJ-56136379 (1) · Sodium Chloride (1) · Tirzepatide (1) · peginterferon alfa-2a (1) · plozasiran (1)
New Zealand (16) · Australia (15) · Canada (10) · Germany (7) · South Korea (7) · United States (7) · Poland (5) · China (4) · Spain (4) · Thailand (4) · United Kingdom (4) · Georgia (3) · Hungary (3) · Italy (3) · Netherlands (3)
Bruce Given, MD (1)
PMID 38682459, PMID 33712437, PMID 34256305, PMID 35695169, PMID 35748699, PMID 35870702, PMID 36513186, PMID 38299639, PMID 38583092, PMID 38804517, PMID 38809174, PMID 38964420, PMID 41422812, PMID 42291067, PMID 42496147, PMID 42717034
2014 (3), 2023 (2), 2015 (1), 2016 (1), 2018 (1), 2019 (1)